Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1 Completed 90 enrolled TG Therapeutics, Inc. SCRI Development Innovations, LLC · collab

NaSingle-groupOpen-labelTreatment

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.

Evaluation	Drug	Modality	Dose	Route
Subject	Umbralisib	Small molecule	50 mg	Oral
Subject	Umbralisib	Small molecule	100 mg	Oral
Subject	Umbralisib	Small molecule	200 mg	Oral
Subject	Umbralisib	Small molecule	400 mg	Oral
Subject	Umbralisib	Small molecule	800 mg	Oral
Subject	Umbralisib	Small molecule	1200 mg	Oral
Subject	Umbralisib	Small molecule	1800 mg	Oral